Clinical trial · no report yet · Phase 2
CANTATA
CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma
- NCT03428217 ↗
- Completed
- Calithera Biosciences, Inc
- 11 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| Podcasts | 6 | |
| X threads | 3 | |
| YouTube | 2 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Advanced Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma
- Interventions
- CB-839; Cabozantinib; Placebo
- Arms
- Pbo-Cabo · Placebo comparator
- CB-Cabo · Experimental
- Enrollment
- 444
- Primary outcomes
- Progression-Free Survival (PFS) as Assessed by the Independent Radiology Committee (IRC)
- Sponsor
- Calithera Biosciences, Inc
- Start
- Apr 24, 2018
- Primary completion
- Aug 31, 2020
- Results posted
- Yes
- Registry record
- NCT03428217 · updated Mar 20, 2023
Publications
linked from the registry- Tannir NM, Agarwal N, Porta C, Lawrence NJ, Motzer R, McGregor B, Lee RJ, Jain RK, Davis N, Appleman LJ, Goodman O Jr, Stadler WM, Gandhi S, Geynisman DM, Iacovelli R, Mellado B, Sepulveda Sanchez JM, Figlin R, Powles T, Akella L, Orford K, Escudier B. Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial. JAMA Oncol. 2022 Oct 1;8(10):1411-1418. doi: 10.1001/jamaoncol.2022.3511. PubMed 36048457